Concepts (156)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Arthritis, Rheumatoid | 36 | 2022 | 158 | 11.120 |
Why?
|
| Atherosclerosis | 17 | 2018 | 100 | 4.330 |
Why?
|
| Carotid Artery Diseases | 13 | 2016 | 34 | 3.920 |
Why?
|
| Cardiovascular Diseases | 12 | 2020 | 237 | 3.370 |
Why?
|
| Leptin | 4 | 2015 | 26 | 1.520 |
Why?
|
| Risk Factors | 23 | 2023 | 1475 | 1.450 |
Why?
|
| Insulin Resistance | 3 | 2019 | 79 | 1.270 |
Why?
|
| Inflammation | 6 | 2022 | 104 | 1.150 |
Why?
|
| Middle Aged | 27 | 2019 | 3601 | 1.060 |
Why?
|
| Humans | 40 | 2023 | 14537 | 1.030 |
Why?
|
| Chemokine CCL2 | 4 | 2014 | 10 | 1.020 |
Why?
|
| Female | 33 | 2023 | 9103 | 0.970 |
Why?
|
| Adipokines | 3 | 2014 | 11 | 0.960 |
Why?
|
| Chemokines | 2 | 2015 | 9 | 0.950 |
Why?
|
| Resistin | 3 | 2014 | 10 | 0.930 |
Why?
|
| Male | 28 | 2019 | 6754 | 0.920 |
Why?
|
| Aged | 19 | 2019 | 1740 | 0.910 |
Why?
|
| Biomarkers | 8 | 2016 | 327 | 0.900 |
Why?
|
| Metabolic Syndrome | 4 | 2014 | 64 | 0.760 |
Why?
|
| Vascular Cell Adhesion Molecule-1 | 5 | 2016 | 25 | 0.720 |
Why?
|
| Carotid Intima-Media Thickness | 11 | 2018 | 108 | 0.720 |
Why?
|
| Intercellular Adhesion Molecule-1 | 4 | 2014 | 20 | 0.690 |
Why?
|
| Adiponectin | 3 | 2014 | 15 | 0.670 |
Why?
|
| Obesity | 2 | 2014 | 367 | 0.660 |
Why?
|
| Antirheumatic Agents | 4 | 2023 | 35 | 0.630 |
Why?
|
| Carotid Arteries | 5 | 2018 | 19 | 0.630 |
Why?
|
| Cross-Sectional Studies | 10 | 2019 | 1422 | 0.610 |
Why?
|
| Plaque, Atherosclerotic | 5 | 2018 | 27 | 0.480 |
Why?
|
| Leukocyte Count | 1 | 2014 | 24 | 0.470 |
Why?
|
| Endothelium, Vascular | 4 | 2016 | 29 | 0.470 |
Why?
|
| Endothelial Cells | 2 | 2015 | 14 | 0.460 |
Why?
|
| Retinol-Binding Proteins, Plasma | 1 | 2014 | 2 | 0.460 |
Why?
|
| Blood Pressure | 6 | 2017 | 317 | 0.460 |
Why?
|
| Heart Diseases | 1 | 2014 | 19 | 0.440 |
Why?
|
| Adult | 13 | 2023 | 5913 | 0.440 |
Why?
|
| Metabolic Diseases | 1 | 2014 | 30 | 0.440 |
Why?
|
| Lipids | 1 | 2013 | 81 | 0.430 |
Why?
|
| Aging | 1 | 2014 | 109 | 0.420 |
Why?
|
| Adiposity | 1 | 2013 | 96 | 0.400 |
Why?
|
| Vulnerable Populations | 2 | 2010 | 30 | 0.400 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 3 | 2016 | 10 | 0.380 |
Why?
|
| Health Services | 1 | 2011 | 51 | 0.370 |
Why?
|
| Depression | 1 | 2011 | 121 | 0.340 |
Why?
|
| E-Selectin | 3 | 2014 | 14 | 0.340 |
Why?
|
| Private Sector | 1 | 2010 | 45 | 0.340 |
Why?
|
| Cost of Illness | 1 | 2011 | 167 | 0.340 |
Why?
|
| Public Sector | 1 | 2010 | 82 | 0.330 |
Why?
|
| National Health Programs | 1 | 2010 | 78 | 0.330 |
Why?
|
| Social Class | 1 | 2009 | 73 | 0.320 |
Why?
|
| Dyslipidemias | 1 | 2009 | 57 | 0.310 |
Why?
|
| Regression Analysis | 4 | 2017 | 133 | 0.300 |
Why?
|
| Prevalence | 4 | 2013 | 1192 | 0.290 |
Why?
|
| South Africa | 9 | 2016 | 7596 | 0.280 |
Why?
|
| Predictive Value of Tests | 4 | 2019 | 188 | 0.280 |
Why?
|
| C-Reactive Protein | 1 | 2007 | 96 | 0.270 |
Why?
|
| Public Health Practice | 1 | 2005 | 7 | 0.260 |
Why?
|
| Health Services Accessibility | 1 | 2008 | 280 | 0.260 |
Why?
|
| Needs Assessment | 1 | 2005 | 29 | 0.250 |
Why?
|
| Disability Evaluation | 1 | 2005 | 22 | 0.250 |
Why?
|
| Quality Assurance, Health Care | 1 | 2005 | 43 | 0.250 |
Why?
|
| Logistic Models | 3 | 2016 | 254 | 0.230 |
Why?
|
| Multivariate Analysis | 4 | 2017 | 171 | 0.230 |
Why?
|
| Cholesterol, HDL | 2 | 2014 | 32 | 0.220 |
Why?
|
| Still's Disease, Adult-Onset | 1 | 2023 | 1 | 0.220 |
Why?
|
| Thromboembolism | 1 | 2023 | 10 | 0.220 |
Why?
|
| Risk Assessment | 3 | 2016 | 225 | 0.210 |
Why?
|
| Gene Expression | 1 | 2022 | 43 | 0.200 |
Why?
|
| Body Mass Index | 3 | 2018 | 321 | 0.200 |
Why?
|
| Vascular Stiffness | 2 | 2019 | 41 | 0.190 |
Why?
|
| Asymptomatic Diseases | 2 | 2017 | 7 | 0.180 |
Why?
|
| Risk Management | 1 | 2020 | 4 | 0.180 |
Why?
|
| gamma-Glutamyltransferase | 1 | 2020 | 6 | 0.180 |
Why?
|
| Severity of Illness Index | 3 | 2016 | 253 | 0.170 |
Why?
|
| Developing Countries | 2 | 2013 | 400 | 0.170 |
Why?
|
| Exercise | 1 | 2022 | 205 | 0.170 |
Why?
|
| Waist-Hip Ratio | 2 | 2012 | 29 | 0.170 |
Why?
|
| Linear Models | 3 | 2016 | 83 | 0.170 |
Why?
|
| Peripheral Arterial Disease | 1 | 2019 | 8 | 0.160 |
Why?
|
| Echocardiography, Doppler | 1 | 2019 | 18 | 0.160 |
Why?
|
| Incretins | 1 | 2019 | 1 | 0.160 |
Why?
|
| Glucocorticoids | 1 | 2019 | 20 | 0.160 |
Why?
|
| Tuberculosis, Miliary | 1 | 1998 | 2 | 0.160 |
Why?
|
| Tuberculosis, Splenic | 1 | 1998 | 2 | 0.160 |
Why?
|
| Ventricular Dysfunction, Left | 1 | 2019 | 47 | 0.160 |
Why?
|
| Ventricular Function, Left | 1 | 2019 | 80 | 0.160 |
Why?
|
| Nicotinamide Phosphoribosyltransferase | 1 | 2018 | 3 | 0.150 |
Why?
|
| Calcium-Binding Proteins | 1 | 2018 | 4 | 0.150 |
Why?
|
| Nerve Tissue Proteins | 1 | 2018 | 18 | 0.150 |
Why?
|
| DNA-Binding Proteins | 1 | 2018 | 20 | 0.150 |
Why?
|
| Interleukin-6 | 2 | 2016 | 51 | 0.140 |
Why?
|
| Comorbidity | 2 | 2016 | 188 | 0.140 |
Why?
|
| AIDS-Related Opportunistic Infections | 1 | 1998 | 195 | 0.140 |
Why?
|
| Rheumatic Diseases | 1 | 2016 | 17 | 0.140 |
Why?
|
| Matrix Metalloproteinase 3 | 1 | 2016 | 5 | 0.140 |
Why?
|
| Lectins | 1 | 2016 | 8 | 0.130 |
Why?
|
| Telomere Homeostasis | 1 | 2016 | 5 | 0.130 |
Why?
|
| Telomere | 1 | 2016 | 17 | 0.130 |
Why?
|
| CD4 Lymphocyte Count | 1 | 1998 | 656 | 0.130 |
Why?
|
| Odds Ratio | 2 | 2016 | 133 | 0.130 |
Why?
|
| Diverticulum | 1 | 1995 | 1 | 0.130 |
Why?
|
| Intestinal Polyps | 1 | 1995 | 1 | 0.130 |
Why?
|
| Cecal Diseases | 1 | 1995 | 3 | 0.130 |
Why?
|
| Cytokines | 1 | 2016 | 107 | 0.130 |
Why?
|
| Tuberculosis, Pulmonary | 1 | 1998 | 324 | 0.120 |
Why?
|
| Hypertension | 2 | 2010 | 419 | 0.120 |
Why?
|
| Kidney | 1 | 2015 | 46 | 0.120 |
Why?
|
| Case-Control Studies | 2 | 2019 | 480 | 0.120 |
Why?
|
| Up-Regulation | 1 | 2014 | 23 | 0.120 |
Why?
|
| Molecular Weight | 1 | 2013 | 13 | 0.110 |
Why?
|
| Blood Glucose | 1 | 2014 | 107 | 0.110 |
Why?
|
| Matrix Metalloproteinase 2 | 3 | 2018 | 11 | 0.110 |
Why?
|
| Pregnancy | 1 | 2019 | 1862 | 0.110 |
Why?
|
| Arterial Pressure | 1 | 2013 | 35 | 0.100 |
Why?
|
| Age Factors | 1 | 2014 | 370 | 0.100 |
Why?
|
| Body Weight | 1 | 2013 | 111 | 0.100 |
Why?
|
| African Americans | 1 | 2012 | 47 | 0.100 |
Why?
|
| Blood Sedimentation | 3 | 2016 | 12 | 0.100 |
Why?
|
| Sex Factors | 1 | 2012 | 227 | 0.100 |
Why?
|
| Joints | 1 | 2010 | 9 | 0.090 |
Why?
|
| Arteries | 1 | 2010 | 18 | 0.090 |
Why?
|
| Waist Circumference | 1 | 2010 | 60 | 0.090 |
Why?
|
| Incidence | 1 | 2011 | 685 | 0.080 |
Why?
|
| Diabetes Mellitus | 1 | 2010 | 146 | 0.070 |
Why?
|
| Surveys and Questionnaires | 1 | 2010 | 563 | 0.070 |
Why?
|
| Tomography, X-Ray Computed | 2 | 1998 | 61 | 0.070 |
Why?
|
| Matrix Metalloproteinase 9 | 2 | 2016 | 9 | 0.070 |
Why?
|
| Glomerular Filtration Rate | 2 | 2018 | 62 | 0.070 |
Why?
|
| Smoking | 1 | 2007 | 100 | 0.070 |
Why?
|
| Treatment Outcome | 1 | 2008 | 889 | 0.060 |
Why?
|
| Follow-Up Studies | 1 | 2005 | 370 | 0.060 |
Why?
|
| Aged, 80 and over | 1 | 2005 | 468 | 0.060 |
Why?
|
| Prospective Studies | 2 | 2015 | 1160 | 0.050 |
Why?
|
| Retrospective Studies | 1 | 2005 | 799 | 0.050 |
Why?
|
| Diastole | 1 | 2019 | 43 | 0.040 |
Why?
|
| Statistics, Nonparametric | 1 | 1998 | 38 | 0.040 |
Why?
|
| Ultrasonography | 1 | 1998 | 77 | 0.040 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 1998 | 150 | 0.040 |
Why?
|
| Gene Expression Regulation | 1 | 2018 | 40 | 0.040 |
Why?
|
| Rheumatoid Factor | 1 | 2018 | 16 | 0.040 |
Why?
|
| Pulsatile Flow | 1 | 2017 | 14 | 0.040 |
Why?
|
| Time Factors | 1 | 2019 | 507 | 0.040 |
Why?
|
| Pulse Wave Analysis | 1 | 2017 | 61 | 0.040 |
Why?
|
| Rupture, Spontaneous | 1 | 2016 | 4 | 0.030 |
Why?
|
| Apelin | 1 | 2016 | 3 | 0.030 |
Why?
|
| Inflammation Mediators | 1 | 2016 | 22 | 0.030 |
Why?
|
| GPI-Linked Proteins | 1 | 2016 | 5 | 0.030 |
Why?
|
| Cardiovascular Agents | 1 | 2016 | 11 | 0.030 |
Why?
|
| Health Status Indicators | 1 | 2016 | 17 | 0.030 |
Why?
|
| Cecal Neoplasms | 1 | 1995 | 1 | 0.030 |
Why?
|
| Prognosis | 1 | 2016 | 199 | 0.030 |
Why?
|
| Diagnosis, Differential | 1 | 1995 | 63 | 0.030 |
Why?
|
| Health Status | 1 | 2016 | 111 | 0.030 |
Why?
|
| Kidney Function Tests | 1 | 2015 | 12 | 0.030 |
Why?
|
| Sensitivity and Specificity | 1 | 2016 | 385 | 0.030 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2015 | 69 | 0.030 |
Why?
|
| ErbB Receptors | 1 | 2013 | 14 | 0.030 |
Why?
|